US 11,739,125 B2
Respiratory syncytial virus (RSV) vaccine
Thomas Kramps, Tübingen (DE); Margit Schnee, Constance (DE); Daniel Voss, Tübingen (DE); and Benjamin Petsch, Tübingen (DE)
Assigned to Cure Vac SE, Tübingen (DE)
Filed by CureVac SE, Tübingen (DE)
Filed on May 11, 2021, as Appl. No. 17/316,834.
Application 17/316,834 is a continuation of application No. 16/168,747, filed on Oct. 23, 2018, granted, now 11,034,729, issued on Jun. 15, 2021.
Application 16/168,747 is a continuation of application No. 15/488,815, filed on Apr. 17, 2017, granted, now 10,150,797, issued on Dec. 11, 2018.
Application 15/488,815 is a continuation of application No. 15/048,439, filed on Feb. 19, 2016, granted, now 9,688,729, issued on Jun. 27, 2017.
Application 15/048,439 is a continuation of application No. PCT/EP2014/002301, filed on Aug. 21, 2014.
Claims priority of application No. PCT/EP2013/002518 (WO), filed on Aug. 21, 2013.
Prior Publication US 2021/0261627 A1, Aug. 26, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 14/005 (2006.01); A61K 39/12 (2006.01); C12N 7/00 (2006.01); A61K 39/155 (2006.01); C07K 16/10 (2006.01); A61K 39/00 (2006.01); A61K 48/00 (2006.01)
CPC C07K 14/005 (2013.01) [A61K 39/12 (2013.01); A61K 39/155 (2013.01); C07K 16/1027 (2013.01); C12N 7/00 (2013.01); A61K 48/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/53 (2013.01); A61K 2039/6031 (2013.01); C07K 2317/24 (2013.01); C12N 2760/18534 (2013.01)] 15 Claims
 
1. A method of stimulating an immune response to Respiratory syncytial virus (RSV) in a subject comprising administering to the subject a pharmaceutical composition comprising an mRNA molecule having a coding sequence encoding a fusion (F) protein of RSV with a deleted C-terminus (F-del) lacking amino acids 554-574 of native RSV-F, said coding sequence being at least 80% identical to the protein coding portion of the sequence of SEQ ID NO: 33, wherein the mRNA comprises from 5′ to 3′: (i) a 5′-cap structure; (ii) a 5′ untranslated region (UTR); (iii) the coding sequence encoding the F protein; (iv) a 3′ UTR; and (v) a poly(A) sequence, wherein the mRNA molecule is complexed with a cationic or polycationic compound.